Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer
Authors:
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 154 (1) , 95-101
Abstract
No abstract availableKeywords
Funding Information
- National Comprehensive Cancer Network
This publication has 30 references indexed in Scilit:
- Improved Survival with Bevacizumab in Advanced Cervical CancerNew England Journal of Medicine, 2014
- Oncogenic mutations in cervical cancerCancer, 2013
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced CancerClinical Cancer Research, 2012
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel SequencingCancer Discovery, 2012
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced CancersPLOS ONE, 2011
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- Genetic Alterations in the K-Ras Gene Influence the Prognosis in Patients With Cervical Cancer Treated by RadiotherapyInternational Journal of Gynecological Cancer, 2011
- COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancerNucleic Acids Research, 2009
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersCancer Research, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008